NOVAVAX INC: revenue
| Value | {"amount": 983705000, "concept": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "currency": "USD"} |
|---|---|
| Period | 2023-01-01 – 2023-12-31 |
| Status | current |
| Entity | NOVAVAX INC |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T09:41:04.438994+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/1b9023fe-09a4-4a46-a8c1-6f0bd993aecc
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001000694-25-000004Retrieved: 2026-08-19T09:41:04.438994+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001000694/revenue/2023-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/1b9023fe-09a4-4a46-a8c1-6f0bd993aecc
History
- supersedes {"amount": 983705000, "concept": "us-gaap:Revenues", "currency": "USD"} (evidence 0001000694-24-000007)